Experience in real clinical practice with new direct acting antivirals in chronic hepatitis C
| Autor: | Federico García-García, Marta Maraver-Zamora, Ana Cabello-Fernández, Manuel Ramos-Lora, Fernando Manuel Jiménez-Macías, Gema Romero-Herrera, Antonio Correia-Varela-Almeida, Manuel Cabanillas-Casafranca |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Daclatasvir Cirrhosis Sofosbuvir Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Chronic hepatitis Internal medicine Ascites medicine 030212 general & internal medicine Prospective cohort study business.industry Ribavirin virus diseases medicine.disease digestive system diseases Surgery Clinical Practice chemistry 030211 gastroenterology & hepatology medicine.symptom business medicine.drug |
| Zdroj: | Medicina Clínica (English Edition). 149:375-382 |
| ISSN: | 2387-0206 |
| Popis: | Introduction and objective Inclusion of direct-acting antivirals into clinical practice in patients with chronic HCV (CHC) has been a milestone in medicine. Patients and methods Analytical, prospective study, involving 126 patients with chronic HCV treated with direct-acting antivirals. Efficacy and safety of treatment and factors associated with failure treatment were evaluated. Results Age 54 ± 10. Male (70%). Cirrhosis (60%). Distribution according to genotypes: G1a (31%), G1b (42%); G3 (14%); G4 (13%). Child–Pugh B and C (n = 15). Naive (56%). SVR rate was (87.3%): Child-A (91%), Child-B (75%) and Child-C (60%). The best cure rates were achieved with a 3D/2D ± ribavirin (SVR = 97.4%; n = 39) and sofosbuvir/ledipasvir ± ribavirin (RVS = 93.1%; n = 29) combination. An SVR rate of Discussion The presence of genotype 3, ascites or dosage of ribavirin 600 mg/day in cirrhotic G1 or G3, who will be treated with sofosbuvir + simeprevir or daclatasvir is recommended where no baseline resistance test is available. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect